Table 2.
Time trend of the percent of all incidence cancer cases presenting with synchronous lung metastasis in the United States from 2010 to 2015, stratified by primary site of origin.
| Site | Percent of all incident cancer cases presenting with synchronous lung metastasis (%) | P -value | Adjusted P-value | Trend | |||||
|---|---|---|---|---|---|---|---|---|---|
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | ||||
| All sites | 3.74 | 3.87 | 4.08 | 4.17 | 4.20 | 4.17 | <0.001 | <0.001* | Increasing |
| Anus, anal canal and anorectum | 1.72 | 1.88 | 2.05 | 1.65 | 2.27 | 2.20 | 0.250 | 1.000 | |
| Bones and joints | 11.31 | 10.90 | 11.18 | 10.10 | 8.52 | 11.83 | 0.522 | 1.000 | |
| Brain | 0.04 | 0.09 | 0.09 | 0.09 | 0.11 | 0.07 | 0.536 | 1.000 | |
| Breast | 1.62 | 1.67 | 1.72 | 1.80 | 1.82 | 1.70 | 0.036 | 0.720 | |
| Cervix uteri | 3.32 | 3.73 | 4.44 | 4.02 | 4.31 | 4.90 | 0.001 | 0.027* | Increasing |
| Colon and rectum | 3.91 | 4.50 | 4.52 | 4.96 | 4.86 | 5.04 | <0.001 | <0.001* | Increasing |
| Corpus uteri | 1.92 | 1.98 | 2.09 | 2.31 | 2.21 | 2.27 | 0.014 | 0.312 | |
| Esophagus | 8.13 | 8.52 | 9.03 | 9.04 | 8.37 | 9.81 | 0.033 | 0.693 | |
| Gallbladder | 3.47 | 4.21 | 5.68 | 5.00 | 4.76 | 5.33 | 0.068 | 1.000 | |
| Kidney and renal pelvis | 7.62 | 8.14 | 8.09 | 8.02 | 8.29 | 8.26 | 0.062 | 1.000 | |
| Larynx | 1.64 | 2.32 | 1.86 | 2.41 | 2.48 | 1.73 | 0.481 | 1.000 | |
| Liver and intrahepatic bile duct | 6.00 | 5.95 | 6.54 | 6.54 | 6.06 | 6.38 | 0.357 | 1.000 | |
| Lung and bronchus | 12.41 | 13.28 | 13.57 | 13.74 | 13.68 | 13.30 | <0.001 | <0.001* | Increasing |
| Melanoma of the skin | 1.83 | 1.71 | 1.78 | 1.92 | 1.70 | 1.64 | 0.224 | 1.000 | |
| Mesothelioma | 6.14 | 6.24 | 5.54 | 7.60 | 4.56 | 6.39 | 0.811 | 1.000 | |
| Oral cavity and pharynx | 1.73 | 1.98 | 2.11 | 2.12 | 2.15 | 2.18 | 0.018 | 0.390 | |
| Other biliary | 5.32 | 5.65 | 5.48 | 5.49 | 6.84 | 6.13 | 0.107 | 1.000 | |
| Ovary | 5.66 | 5.32 | 5.94 | 5.13 | 5.36 | 5.78 | 0.963 | 1.000 | |
| Pancreas | 8.98 | 8.79 | 9.69 | 9.84 | 9.96 | 9.94 | <0.001 | 0.006* | Increasing |
| Peritoneum, omentum and mesentery | 6.09 | 5.12 | 7.40 | 5.66 | 8.06 | 7.16 | 0.168 | 1.000 | |
| Prostate | 0.34 | 0.31 | 0.49 | 0.50 | 0.58 | 0.64 | <0.001 | <0.001* | Increasing |
| Small intestine | 2.79 | 2.32 | 1.61 | 1.95 | 2.65 | 2.37 | 0.814 | 1.000 | |
| Soft tissue including heart | 8.77 | 8.13 | 8.03 | 7.84 | 8.25 | 8.26 | 0.586 | 1.000 | |
| Stomach | 4.70 | 4.25 | 4.60 | 4.74 | 4.94 | 4.92 | 0.122 | 1.000 | |
| Testis | 6.47 | 7.62 | 6.55 | 8.14 | 6.57 | 7.08 | 0.740 | 1.000 | |
| Thyroid | 1.47 | 1.25 | 1.24 | 1.32 | 1.43 | 1.50 | 0.321 | 1.000 | |
| Ureter | 3.37 | 4.06 | 3.64 | 3.25 | 3.54 | 4.29 | 0.693 | 1.000 | |
| Urinary bladder | 1.07 | 1.21 | 1.29 | 1.21 | 1.40 | 1.66 | <0.001 | <0.001* | Increasing |
| Vulva | 1.67 | 1.61 | 1.20 | 1.01 | 0.97 | 1.07 | 0.053 | 0.998 | |
P-value represents those obtained from Cochran-Armitage tests and the adjusted P-values were corrected for multiple-testing. The direction of the change over time was represented in the Trend column where the test for trend was statistically significant.
*
Statistically significant.